asco@alo33:163013 JSONTXT

{"project":"ASCO_abstracts","denotations":[{"id":"T1","span":{"begin":96,"end":114},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":457,"end":475},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":488,"end":507},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":530,"end":546},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T11","span":{"begin":563,"end":572},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T12","span":{"begin":1777,"end":1795},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0002447"},{"id":"A2","pred":"mondo_id","subj":"T1","obj":"0006003"},{"id":"A3","pred":"mondo_id","subj":"T1","obj":"0011962"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"0002447"},{"id":"A5","pred":"mondo_id","subj":"T4","obj":"0006003"},{"id":"A6","pred":"mondo_id","subj":"T4","obj":"0011962"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"0002447"},{"id":"A8","pred":"mondo_id","subj":"T7","obj":"0006003"},{"id":"A9","pred":"mondo_id","subj":"T7","obj":"0011962"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"0005278"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"0004993"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"0001416"}],"text":" Background: Multiple factors linked to etiology, clinical course and prognosis in to types of endometrial cancer endometrioid type I and non-endometrioid type II cancer have been recognised .These include alterations in concentrations of estrogen and progesterone hormones, mutations in MMR mismatch repair genes, PTEN, TP53, beta-catenin, disturbed signalling pathays e.g. PI3KAKT . Hoever, in several studies, including the data of Epidemiology of Endometrial Cancer Consortium, endometrial cancers and those of type II serous carcinoma and clear-cells carcinoma in particular proved to be more heterogenous than expected 1 ,-2, 3 . Methods: The study manifested a multi-centre character. Using sections of paraffin-embedded preparations and immunocytochemistry ith application of specific antibodies, in 115 patients ith EC type I and in 31 patients ith EC type II, the expression of ER xDF;1, ER x2202;, PR and BRCA1 as estimated. Results: Expression of ER xDF;1 as augmented in USC type II , in cancers of a poor differentiation G3 , it as more pronounced in cancers of an increased clinical advancement according to FIGO. Expression of ER x2202; as detected in the endometrioid type I cancer manifesting good histological differentiation G1or G2 and a lo clinical degree of advancement according to FIGO. In over 50 percent cases of EC type II a mutation as detected in BRCA1, associated ith a decreased expression of ER x2202;. Conclusions: An augmented expression of ER xDF;1 in EC as linked to poor prognosis in type II EC. Higher expression of ER x2202; in type I EC of increased maturity as associated ith a good prognosis. It seems that type II EC is partially connected to BRCA1 mutation.,J Clin Oncol 34, 2016 suppl; abstr e17118 ,Publication Only Gynecologic Cancer \n"}